Li-Na He

A CT‐based radiomics model to predict subsequent brain metastasis in patients with ALK‐rearranged non–small cell lung cancer undergoing crizotinib treatment

Li Zhang, Haifeng Li, Yongluo Jiang, 2022, Thoracic cancer.

Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer

Shaodong Hong, L. Luo, Chen Chen, 2022, Journal of Cancer Research and Clinical Oncology.

PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma

Sha Fu, Shaodong Hong, Chen Chen, 2022, Frontiers in Immunology.

Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus

Li Zhang, Haifeng Li, Shaodong Hong, 2021, Cancer Immunology, Immunotherapy.

Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in the Prediction of Pancreatic Cancer Patients’ prognosis: a retrospective study

Li-Na He, Yungu Chen, Y. Tsang, 2019 .

Inhibition of Dengue virus 2 replication by artificial micrornas targeting the conserved regions.

Xue-jun Wang, Sheng-qi Wang, Li-Na He, 2013, Nucleic acid therapeutics.

Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer

Ping Chen, Hui Yu, Xiuyu Cai, 2021, Cancer Immunology, Immunotherapy.

Early on-treatment tumor growth rate (EOT-TGR) determines treatment outcomes of advanced non-small-cell lung cancer patients treated with programmed cell death protein 1 axis inhibitor

Yanlin Zhou, Yu Wang, Y. Jiang, 2022, ESMO open.